Key Highlights
- Jaguar Health (NASDAQ:JAGX) rose 18.8% to USD 5.62 on October 6, 2026, but a catalyst for that session was not found in company filings or releases we could review.
- Two reverse splits this year, 1-for-35 on April 30 and 1-for-15 on September 17, mean prices are not comparable with last year, and one account showed a spike to a USD 34.46 close.
- Second-quarter Revenue was USD 1.225 million with a net loss to common holders of USD 12.69 million, so Jaguar Health (NASDAQ:JAGX) remains a loss-making micro cap.
- The company says its crofelemer clinical package for microvillus inclusion disease should be ready by the end of 2026, with a new drug application targeted for the second quarter of 2027.
An 18.8% Move With No Filed Trigger
Published market data showed Jaguar Health (NASDAQ:JAGX) gaining 18.8% to USD 5.62 on October 6, 2026. We searched the company's recent releases and filings and found no announcement dated October 5 or 6, so the cause of the day's move is unverified. The shares trade on the Nasdaq Capital Market. Other healthcare micro caps showed similar double-digit gains the same day, including Modular Medical and Lexaria Bioscience, which suggests a broad appetite for small, volatile names rather than one company event. That reading is an inference, not a reported fact. Daily gains of this size on thinly traded stocks often reverse, and the sessions in late September show how fast prices can swing.
Two Reverse Splits and a Violent September
Jaguar effected a 1-for-35 reverse split on April 30, 2026, and a 1-for-15 split effective September 17, 2026, after stockholder approval in April, to support Nasdaq listing compliance. One published account said the shares rose from about USD 2.83 to over USD 41 on September 22 and closed at USD 34.46, then fell to USD 7.06 two sessions later, before gaining about 32% on September 25 to roughly USD 9.32. The same account cited 342,780 shares outstanding after the split, a figure not confirmed in a filing. A float that small lets a handful of trades move the price sharply, a mechanism that explains the October 6 gain and the risk behind it.
Results, Funding and What to Watch
Jaguar licensed U.S. rights to Mytesi and Canalevia-CA1 to Future Pak in January 2026. First-quarter revenue was USD 20.3 million, mostly USD 19.1 million of license revenue. Second-quarter revenue fell 59% to USD 1.225 million, with a net loss to common holders of USD 12.69 million, or USD 15.68 per share, reported on August 19. A USD 2 million non-dilutive holdback from Future Pak was received in August. Cash and cash equivalents were not disclosed in the release, so runway is unverified. The main risks are dilution from future capital raises, dependence on one ingredient, crofelemer, and the Nasdaq listing rules. The third-quarter report date has not been announced.
Where Things Stand
Jaguar Health (NASDAQ:JAGX) rose 18.8% on October 6, 2026 most likely because a very small float amplified buying interest in a volatile healthcare name, although no company announcement explains it. Two reverse splits, a USD 34.46 close in September and a USD 5.62 price now show how unstable trading has been. Revenue has dropped since the Future Pak licensing deal, and the pipeline depends on crofelemer filings planned for 2027. Investors should treat the price as speculative and watch for financing news, Nasdaq notices and the next quarterly report.






Please wait processing your request...